In 36 patients with newly diagnosed HR-deficient stage III/IV ovarian cancer, neoadjuvant niraparib gave a lower pre-surgery response rate than platinum-taxane chemotherapy (31.6% vs 70.6%); the cohort closed early for futility. Grade ≥3 adverse events: 42% vs 59%.
RCTn = 36
Westin et al. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial